Upload
ttongson
View
212
Download
2
Tags:
Embed Size (px)
Citation preview
Management of ovarian cancer
in pregnancy
Charuwan M.D.
Outline Epidemiology Clinical manifestation Investigations Tumor marker Extent of surgery Chemotherapy
Epidemiology In population- based hospital registry
series of malignancies during pregnancy:
- breast
- thyroid- cervix- Hodgkin lymphoma
- ovarian cancer
EpidemiologyLifetime risk of developing ovarian
cancer is 1.4 %0.2 – 2 % of pregnancies are
complicated by adnexal mass
1 – 6 % malignancy
- 1991 – 1999 - N: 4,846,505- 9375 ovarian
masses diagnosed during pregnancy - 87 ovarian cancer (0.93%)
- 115 LMP (1.2%)
Leiserowitz GS et al:Gynecol Oncology2006
Review of publications(1958 – 2007 )
- Mean age 33 years (range 23 – 46 yr)
- FIGO stage I: 59 % stage II: 5 % stage III: 26 % stage IV: 10 %
Palmer J et al:BJOG2009
Clinical manifestations- Prior to the use of U/S:
most adnexal mass remained unrecognized until C/S or symptomatic
Retrospective series:8330 C/S
68 incidental adnexal masses > 5 cm1 malignancy
Dede M, et al:Int J Gynecol Cancer 2007
U/S + Cesarean section
Incidental detection of asymptomatic adnexal mass
Clinical manifestation Nonspecific symptoms:
- abdominal or back pain- constipation- abdominal distension- urinary symptoms
Palpable mass from PV Acute abdominal pain: torsion
U/S- Size > 10 cm + tumor growth
rate > 3.5 cm/week :
Risk of malignancy
Yen CF, et al: Risk analysis of torsion and malignancy for adnexal masses during pregnancy, Fertil Steri 2009.
U/SOvarian mass < 5 cm :
benign(follicular cyst or corpus luteal cyst)
The majority of persistent adnexal mass ≥ 5 cm are dermoid
MRI U/S is inconclusive or insufficient
data Fetus does not expose to ionizing
radiation Soft tissue pathology : - peduncutated myoma
degenerated myoma- endometrioma- massive ovarian edema
CT CT pelvis: fetal ionizing radiation dose
0.035 Gy Fetal radiation exposure < 0.05 Gy: ไม่�เพิ่��ม่
abortion, congenital anomalies, growth restriction or perinatal mortality
Possible increase risk of developing childhood cancer.
Iodinated contrast: transient suppression of the fetal thyroid.
DDxMost common are benign: simple
cyst, hemorrhagic cyst, leiomyomaMost common benign complex mass:
dermoid, endometrioma, hydrosalpinx and cystadenoma
Uncommon: hyperreactio luteinalis, theca lutein cyst and luteoma
DDxAbdominal pain:
- torsion or rupture of ovarian neoplasm
- degeneration of leiomyoma
DiagnosisDefinitive diagnosis bypathologic examination
Tumor marker
Tumor marker in pregnancy Several tumor marker are difficult to
interpret in pregnancy. Oncofetal antigen: AFP, CEA, HCG
and CA – 125 Oncofetal antigens are involved in
biological functions associated with fetal development, differentiation and maturation
Tumor marker in pregnancy The levels are normally elevated
during gestation and fluctuate with gestation age.
They may be abnormally elevated due to abnormal placentation or fetal abnormalities(preeclampsia, Down syndrome, open neural tube defect).
CA 125CA 125 can produce by normal tissues including endometrium
May be elevated during early gestation and immediately following delivery
May be helpful between 15 wk – delivery.
CA 125 level: 1,000 – 10,000 Suggest cancer
75 – 150 could be pregnancy or ovarian cancer
Alpha - fetoproteinDuring pregnancy,
- AFP expressed as multiples of median (MoM) because these value are easy to derive, more stable and allow for interlaboratory variation
Abnormal MSAFP > 2 – 2.5 MoM > 9 MoM should concern for germ cell
tumor if absence of fetal abdominal defect or anencephaly
Alpha – fetoprotein
High MSAFP levels(often > 1000 ng/ml)
- EST- Embryonal carcinoma- Mixed tumor
MSAFP < 500 ng/ml : NTD
Lactate dehydrogenaseLDH is not elevated in normal pregnancy
LDH can elevate in severe preeclampsia and HELLP syndrome
LDH is a reliable marker for diagnosis and FU in pregnancy
Inhibin AInhibin A is made in the
developing placenta:
Inhibin A may be measure for screening Down syndrome (average 2 fold higher)
Early pregnancy
Sonographer should evaluate ovaries ifabnormal serum down screening test
Ovarian tumor in pregnancy
Epithelial ovarian tumor 50 % LMP LMP in pregnancy may exhibit
atypical characteristics suggestive of invasive cancer:
- nuclear enlargement- multifocal microinvasion
Informed pathologist + pathologist skill
Germ cell tumor3/4 of germ cell tumor in
pregnancy: dysgeminomaDysgeminoma are bilateral:
10 – 15%, other germ cell tumor are almost always unilateral
Sex cord- stromal tumors50% granulosa cell tumor1/3 sertoli leydig cell tumorMost of these tumor: unilateral20 % presented with intraperitoneal
hemorrhage and/or hemorrhagic shock
10 – 15 % of stromal tumor secrete androgen and produce virilization
Management
ManagementInterdisciplinary consultation:
- MFM- Gyne -
oncology- Pediatrics- Pathology
I/C for surgeryPersist into second trimesterTumor size > 10 cmSolid or mixed solid and cystic
highly suspicious for malignancy
For early stage and to prevent adnexal torsion, rupture or obstruction of labor
Time to surgery Early second trimester
- Organogenesis is complete: minimizing risk of drug induced teratogenesis- Risk of pregnancy loss is low.- Cystectomy or oophorectomy does not affect progesterone concentration- Almost all functional cyst resolved.- Spontaneous pregnancy losses due to intrinsic fetal abnormalities occur in first trimester
Surgical Approach
Laparoscopy with adnexal mass during pregnancy
Laparoscopy may decrease uterine blood by increasing intraabdominal pressure
- Fetal hypotension, hypoxia
- Uterine perforation by trocar or Veress needle
- Fetal acidosis by CO2 absorption
Surgical approach
Adequate midline incision: minimize need to manipulate gravid uterus
Ascites collection or peritoneal washing
Carefully inspected and palpated contralateral adnexal mass
Preop imaging/intraop. finding suggested benign
Suspected malignancy: frozen sectioncystectomy / USO
Surgical approach- Resection of the contralateral
ovary is not required unless bilateral disease is identified:
This decision must await the frozen section
Surgical approachAll suspicious lesions should be
biopsied.Early stage: considered adequate
surgical stagingAdvance stage: debulking tumor
LMP: adequate surgery
Extent of surgery Clinical judgementBalancing the extent of surgery/expected benefit
It is rare that removal of gravid uterus is required.
Return for secondary cytoreduction following chemotherapy and successful completion of the pregnancy.
Termination of pregnancySome woman diagnosed with ovarian cancer in early pregnancy may choose to undergo TOP.
Early stageT he goal of initial surgery sho
uld be to completely resect all r esidual disease, without disturbi
ng the pregnancy
Early stageChemotherapy
- Stage IA,IB with G2, 3
- Stage IC, II with any grade- Clear cell
Early stage No residual tumor 271 nonpregnant
women:- Cisplatin/observe- Immediate Cisplatin+P32/Cisplatin at the time of
relapseDelay chemotherapyUntil after delivery
No difference of OS
Bolis G: Ann Oncol 1995
Early stageGross residual tumor:
- possibly should not delay chemotherapy > 6 – 8 wks after surgery
Chemotherapy
Chemotherapy during pregnancyRare eventIf indicated: prefer in the second or early third trimester.
Chemotherapy Category D Chemotherapy preferentially kill
rapidly proliferating cells fetus
The risk of spontaneous abortion, fetal death and major malformation depend on drug agent and gestational age.
ChemotherapyFirst 4 wks: all or none phenomenon(either pregnancy loss or no adverse effect)
4 wk – first trimester(organogenesis): risk of fetal malformation
Chemotherapy and breastfeeding
Immune suppressionImpaired growthAssociation with carcinogenesis
American Academy of Pediatrics
Chemotherapy Counselling Immediate/delay chemotherapy Ethical consideration
- patient autonomy- concept of beneficence- nonmalfeasance
Limited data, uncommon clinical problem in pregnancy.Less data on long-term outcomes in offspring
Epithelial ovarian cancerPlatinum and taxane:Limited data
Platinum derivatives during pregnancy Systematic review: 43 pregnancies - 3 IUGR
- 3 Preterm birth- 2 Oligohydramnios- 1 Polyhydramnios
- 1 Ventriculomegaly- 1 Microphthamus
Chemotherapy and breastfeedingEpithelial group:
- Cisplatin is transferred into breast milk (WHO)- Carboplatin: no data- Paclitaxel is lipophilic: potential to be concentrated in breast milk.
TaxaneFew case reports: short term safety but long term outcomes have not been reported.
ICON study: single agent carboplatin
Chemotherapy 217 pregnant women(1983 - 1995)
- congenital abnormalities 18- chromosomal abnormalities 2- still birth 4- spontaneous abortion 15
Multiagent > single agent (25% vs 10%)
Chemotherapy
Second and third trimesterfetal malformation 1.3%IUGRPrematurityLow birth weight
Fetal toxicities: BM suppression, ototoxicity
50 %
Chemotherapy> 35 wks or 3 wks before
delivery: should be avoided- transient myelosuppression- potential bleeding- sepsis- death at the time of delivery
Chemotherapy in EOC Single agent platinum during
pregnancy, followed by PT regimen postpartum.
At least in theory, this approach should be feasible without compromising maternal survival.
Summary of EOC- Surgery :
O ptimal surgical cytoreduction to the e xtent possible consistent with maternal an
d fetal safety. - Chemotherapy is indicated:
- carboplatin during pregnancy
- a fter delivery: PT regimen
Germ cell tumor• Maximal surgical cytoreduction is usually
undertaken initially. • A djuvant chemotherapy is recommended
to reduce the risk of recurrence
S tage IA dysgerminomasS tage I grade I immature teratomas
Except
Germ cell tumorBEP regimenEtoposide: IUGR, neonatal BM
suppression but there are no report of fetal malformations
Germ cell tumor Reports suggest that delaying
chemotherapy increase risk of recurrence.
Chemotherapy should be delayed until afterfirst trimester, but not longer
Chemotherapy and breastfeeding Germ cell tumor: BEP or PVB
- Etoposide is excreted into breastmilk- Cisplatin is C/I by WHO
Summary of Germ cell tumorSurgery:
maximal surgical cytoreduction.
Chemotherapy should be delayed at least until completi
on of the first trimester of pregnancy.
Sex cord stromal tumorSlow progressive.Suggest surgery alone during pregnancy
Chemotherapy can be deferred to postpartum
ChemotherapyReference Cell type GA at
treatChemo
Outcome
Henderson CE,(1993)King LA (1991)Malfetano JH (1990)Tomlinson MW(1997)Malone JM (1986)Kim DS (1989)Metz SA (1989)Weed JC (1979)Hobelt D (1994)
SerousSerousSerousSertoli-LESTESTESTESTEST/Imma
201616242616172320
PCPCPCPCPVBVACVACVACBEP
Preterm(36)Preterm(36)TermE C/S (34)E C/S (32)TermTermPreterm(33)Term
Timing of deliveryEarly delivery to avoid fetal exposure to chemotherapy is reasonable if lung maturity can be documented and GA ≥ 34 wks.
PrognosisNo evidence that pregnancy
worsen prognosis than nonpregnancy matched for histology, stage and grade.
75 % pregnant women are early stage
5 yr survival : 72 – 90 %
Adnexal mass in C/S
• Should be removed: complete surgical removal is preferred over aspiration and cytologic evaluation.
• Frozen section: if available
Summary and recommendations Most adnexal massed in pregnant
women are benign and asymtomatic. Suggested surgery:
- persist into second trimester- > 10 cm - solid or mixed solid-cystic
Multidisciplinary consultation: balancing maternal and fetus risk
Summary and recommendations
Extent of surgery: clinical judgement + balancing the extent of surgery/expected benefit.
When chemotherapy is indicated: started after first trimester and should be avoided 3 wks before delivery
Thank you for your attention